Abstract
Summary
Nasal Chondrocytes are safe and feasible for tissue engineering approaches in articular cartilage repair.
Introduction
As compared to articular chondrocytes (AC), nasal septum chondrocytes (NC) proliferate faster and have a higher and more reproducible capacity to generate hyaline-like cartilaginous tissues. Moreover, the use of NC would allow reducing the morbidity associated with the harvesting of cartilage biopsy from the patient. The objective of the present study was to demonstrate safety and feasibility in the use of tissue engineered cartilage graft based on autologous nasal chondrocytes for the repair of articular defect in goats.
Methods
Isolated autologous NC and AC from 6 goats were expanded and GFP-labelled before seeding 4×104 cells/cm2 on a type I/III collagen membrane (Chondro-Gide®, Geistlich). After 2 weeks of chondrogenic differentiation 2 NC- and 2 AC-based grafts were implanted into chondral defects (6mm diameter) of the same posterior stifle joint. Repair tissue was harvested after 3 or 6 months and the decalcified samples evaluated according to O'Driscoll. Furthermore, samples from the surrounding fat pad, ligament, synovium, tendon and patellar cartilage were harvested and isolated cells tested for GFP-positivity after expansion using FACS.
Results
No surgical complication or signs of inflammation occurred in any of the animals. GFP-positive cells were detectable in the repair tissue, indicating the contribution of the implanted cells to the newly formed cartilage. The O'Driscoll score of the repair tissue increased from 8.6 and 7.6 after 3 months to 14.1 and 12.4 after 6 months for nasal and articular grafts, respectively. Surrounding tissues showed no or very low (fat pad 0–0.36%) migration of the grafted cells.
Conclusion
Our results demonstrate the use of NC as safe and feasible for tissue engineering approaches in articular cartilage repair. The repair tissue-quality generated by NC-grafts was demonstrated to be at least comparable to that of AC-grafts, thus opening the way for clinical test of a novel therapeutic strategy.
